Trinity Biotech (TRIB) Cash & Current Investments (2009 - 2025)

Trinity Biotech has disclosed Cash & Current Investments across 17 years of filings, most recently posting $5.1 million for Q4 2025.

• Cash & Current Investments for Q4 2025 came in at $5.1 million, down 3.66% year-over-year; the trailing twelve-month figure through Dec 2025 was $5.1 million (down 3.66% YoY), and the FY2025 annual result was $5.1 million, up 33.21% from the prior year.
• Cash & Current Investments came in at $5.1 million for Q4 2025 at Trinity Biotech, up from $1.6 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $32.3 million in Q1 2021 to a low of $152000.0 in Q1 2023.
• The 5-year median for Cash & Current Investments is $6.6 million (2022), against an average of $12.5 million.
• Across the five-year window, Cash & Current Investments soared 143.71% in 2021 and sank 99.42% in 2023, its largest moves.
• Trinity Biotech's Cash & Current Investments stood at $25.9 million in 2021, then plunged by 74.12% to $6.7 million in 2022, then plunged by 42.31% to $3.9 million in 2023, then surged by 37.84% to $5.3 million in 2024, then dropped by 3.66% to $5.1 million in 2025.
• The last three Cash & Current Investments figures came in at $5.1 million (Q4 2025), $1.6 million (Q2 2025), and $5.3 million (Q4 2024), per Business Quant data.